Blackfan Circle Innovations

Blackfan Circle Innovations is a Deerfield-created company formed to support a translational research collaboration with Boston Children's Hospital. The organization provides funding, operational support, and drug development expertise to advance Boston Children's research programs toward Investigational New Drug readiness and potential commercialization. Its focus is broad across high-need therapeutic areas, with particular relevance to rare and complex pediatric diseases. Publicly disclosed activity indicates an emphasis on early-stage therapeutic development rather than a commercial-stage product portfolio. The first announced project was a gene therapy program arising from the lab of Friedhelm Hildebrandt focused on monogenic pediatric kidney disease.